Small, single-center studies suggest that deleterious germline CHEK2 variants may contribute to the development of non-Hodgkin lymphoma (NHL) [19, 20], myeloproliferative neoplasms (MPNs) [21, 22], and myelodysplastic neoplasms (MDS) [23, 24]. The gene discussed is CHEK2; the disease is non-Hodgkin lymphoma.